Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Grants Non-Exclusive License to RNAi IP to Koken

Premium

Alnylam Pharmaceuticals said this week that it has granted a non-exclusive license to certain of its RNAi intellectual property to Japan's Koken for use in the manufacture and sale of RNAi research products.

"We are pleased to grant Koken a license to manufacture and provide siRNA reagents to its industry and academic customers around the world for research purposes," Alnylam Vice President of Business Development Jason Rhodes said in a statement. "With more than 15 license agreements with global research product suppliers, including five in the Asian markets alone, we believe the vast majority of industrial sales of RNAi products for research purposes are currently being made under a license from Alnylam."

Specific terms of the arrangement were not disclosed.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.